32 results
Clinical and echocardiographic outcomes among the first 500 patients treated with a dedicated transcatheter aortic valve for pure aortic regurgitation in the Align-AR clinical trial
31 Mar 2025
Jonathan Curio interviews Raj Makkar about the results of the Align-AR trial which he presented during the ACC.25 in Chicago.
Author
Author
Routine cerebral embolic protection in transcatheter aortic valve implantation: the British Heart Foundation (BHF) PROTECT-TAVI trial
29 Mar 2025
Aaysha Cader and Ali Nazmi Calik provide their take on the BHF PROTECT-TAVI trial, presented by Rajesh Kharbanda at ACC.25 in Chicago.
Author
Author
The main results of the phase 3 Reverse-it trial
02 Apr 2025
Luis Ortega-Paz interviews Deepak L. Bhatt about the results of the Phase 3 Reverse-it trial which he presented during the ACC.25 in Chicago.
Author
Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.
Author
Author
Dapagliflozin in patients undergoing transcatheter aortic valve implantation (DapaTAVI)
10 Apr 2025
Chiara De Biase interviews Sergio Raposeiras-Roubin about the results of the DapaTAVI trial which he presented during the ACC.25 in Chicago.
Author
Author
Primary and secondary outcomes of the Women's Ischemia Trial to reduce events in non-obstructive coronary artery disease (WARRIOR)
31 Mar 2025
Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.
The manuscript for this trial has not been published and all assumptions are based upon the presentation.
Author
PCRonline @ ACC.25 Scientific Sessions
07 Feb 2025
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25
The RELIEVE-HF study: is an atrial septal shunt beneficial in HFrEF?
07 Apr 2024
Charles Fauvel provides his take on the RELIEVE-HF study outcomes presented by Gregg W. Stone at ACC.24 in Atlanta.
Author
Empagliflozin after acute myocardial infarction: Results of the EMPACT-MI Trial
07 Apr 2024
Mirvat Alasnag interviews Javed Butler about the EMPACT-MI trial which he presented at ACC.24 in Atlanta.
Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of first hospitalization for heart failure or death from any...
Author
Author
CSL112 (Apolipoprotein A-I) infusions and cardiovascular outcomes in patients with acute myocardial infarction (ApoA-I event reducing in ischemic syndromes II (AEGIS-II) Trial): Primary trial results
06 Apr 2024
Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.
ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.
Author
Author
